What are the recommended dosing, administration schedule, monitoring parameters, and contraindications for atomoxetine in treating attention‑deficit/hyperactivity disorder?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 11, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Atomoxetine Treatment for ADHD

Atomoxetine is an FDA-approved nonstimulant medication for ADHD that should be initiated at 0.5 mg/kg/day in children and adolescents under 70 kg (or 40 mg/day in those over 70 kg and adults), titrated to a target dose of 1.2 mg/kg/day (or 80 mg/day), with a maximum of 1.4 mg/kg/day or 100 mg/day, whichever is lower 1.

Dosing and Administration

Initial Dosing Strategy

  • Children/adolescents ≤70 kg: Start at 0.5 mg/kg/day, target 1.2 mg/kg/day, maximum 1.4 mg/kg/day 1
  • Children/adolescents >70 kg and adults: Start at 40 mg/day, target 80 mg/day, maximum 100 mg/day 1
  • Available formulations: Capsules (10,18,25,40,60,80,100 mg) and oral solution (4 mg/ml) 2

Administration Schedule

Atomoxetine can be administered once daily in the morning or divided into two doses (morning and late afternoon/early evening) 1. Once-daily morning dosing provides continuous symptom relief lasting into evening and morning hours 3. To minimize gastrointestinal side effects, the daily dose can be split or administered in the evening only if needed 2.

Critical Dosing Considerations

  • Avoid rapid titration: Increasing dosage too quickly causes somnolence and gastrointestinal symptoms 4
  • Allow adequate treatment duration: Effects typically emerge after 6-12 weeks, unlike stimulants which work immediately 2
  • Maintain target dose for 4-6 weeks before judging efficacy 5
  • Dose adjustments required for:
    • CYP2D6 poor metabolizers (7% of population): Higher plasma levels and longer half-lives increase adverse effects 2
    • Concomitant strong CYP2D6 inhibitors (e.g., some SSRIs): Can elevate atomoxetine levels 2
    • Hepatic impairment: Dose reduction necessary 1

Common Pitfall: Underdosing

Real-world data shows adults frequently receive ~60 mg/day instead of the recommended 80 mg/day target, leading to suboptimal outcomes 5. Adolescents maintained long-term benefit better with 1.4 mg/kg/day than 0.8 mg/kg/day 6.

Pre-Treatment Screening and Contraindications

Mandatory Cardiac Evaluation

Before initiating atomoxetine, obtain 4:

  • Personal cardiac history: Specific cardiac symptoms, syncope, palpitations
  • Family history: Sudden death, Wolff-Parkinson-White syndrome, hypertrophic cardiomyopathy, long QT syndrome
  • If risk factors present: Perform ECG and consider pediatric cardiology referral if abnormal 4

Absolute Contraindications 1

  • Hypersensitivity to atomoxetine
  • Use within 2 weeks of MAOI discontinuation
  • Narrow-angle glaucoma
  • Pheochromocytoma or history thereof
  • Severe cardiovascular disorders that may deteriorate with increased heart rate/blood pressure

Screen for Bipolar Disorder

All patients must be screened for bipolar disorder before starting atomoxetine 1. Atomoxetine can precipitate manic episodes in susceptible individuals 2.

Monitoring Parameters

Critical Safety Monitoring

Suicidality (FDA Black Box Warning): Monitor closely for suicidal ideation, clinical worsening, and unusual behavioral changes, especially during the first few months and at dose changes 2, 1. This risk applies to children and adolescents; adult trials did not show increased risk 2.

Cardiovascular monitoring:

  • Heart rate and blood pressure at baseline and regularly during treatment 4
  • Atomoxetine increases HR and BP (unlike guanfacine/clonidine which decrease them) 4
  • Monitor for orthostasis and syncope 1

Hepatic function: Watch for jaundice or laboratory evidence of liver injury; discontinue immediately if hepatitis develops (extremely rare) 4, 1

Growth parameters: Monitor height and weight in pediatric patients 4, 1. Growth delays occur in first 1-2 years with return to expected measurements after 2-3 years, particularly in children taller/heavier than average before treatment 4.

Psychiatric symptoms: Monitor for emergence of psychotic/manic symptoms, aggressive behavior, or hostility 1

Urinary function: Watch for urinary hesitancy and retention 1

Priapism: Educate patients/families about this rare but serious adverse effect requiring immediate medical attention 1

Common Adverse Effects

Most frequent adverse effects in children/adolescents 2, 1:

  • Nausea, vomiting
  • Fatigue, somnolence
  • Decreased appetite
  • Abdominal pain

These effects are generally less frequent and less pronounced than with alpha-2 agonists (clonidine/guanfacine) 2. Atomoxetine shows lower effects on appetite and fewer growth problems compared to stimulants 2.

Clinical Context and Role in Treatment

Atomoxetine is generally recommended as second-line treatment after stimulants 2, as stimulants demonstrate larger effect sizes 2. However, atomoxetine offers specific advantages:

  • Non-controlled substance status
  • Around-the-clock symptom coverage
  • May be preferred when stimulants are contraindicated, not tolerated, or ineffective
  • Can be used off-label as adjunctive therapy with stimulants (limited evidence) 4

Atomoxetine is NOT recommended as first-line treatment in preschool-aged children (4-6 years) due to lack of sufficient rigorous study in this population 4.

References

6
Research

Atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder.

Journal of child and adolescent psychopharmacology, 2009

Related Questions

What is the appropriate atomoxetine dose for a child weighing 74 lb who has already completed the initial low‑dose trial?
Can I increase my Strattera (atomoxetine) dose from 40 mg to 60 mg in the morning?
For an ADHD patient on atomoxetine (Strattera) 40 mg who experiences improvement that wanes toward the end of the day, what dosing adjustments are recommended?
What is a safe starting dose of atomoxetine (Strattera) for a 14‑year‑old male with ADHD and depression, weighing 50 kg, who cannot tolerate stimulant medications?
Is it appropriate to add Strattera (atomoxetine) for attention‑deficit/hyperactivity disorder to my current treatment with sertraline and aripiprazole, and how should it be dosed and monitored?
What should be monitored in a patient after an above‑knee amputation who received a pre‑operative unfractionated heparin infusion?
What is the efficacy of EquiShield as an immune‑boosting supplement?
What is the difference between D-dimer and fibrin degradation products?
Are prophylactic antibiotics required following an above‑knee amputation?
What next chemotherapy regimen should be given for an acute myeloid leukemia patient who relapses during daunorubicin‑cytarabine treatment?
How should I assess and manage a patient presenting with bilateral pitting pedal edema, shortness of breath, generalized weakness, and a feeling of heaviness?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.